1671.6p 13.8 0.8%
Last Trade - 20/09/19
| Market Cap | £83.39bn |
| Enterprise Value | £111.99bn |
| Revenue | £31.76bn |
| Position in Universe | 17th / 1829 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | TTM | 2019E | 2020E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2019
|
31st Dec 2020
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
| Last Annual | December 31st, 2018 |
| Last Interim | June 30th, 2019 |
| Incorporated | December 6, 1999 |
| Public Since | May 22, 1972 |
| No. of Shareholders: | 109,855 |
| No. of Employees: | 95,490 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE4GD UK 50, FTSE All Share , FTSE All Share Health Care , FTSE All Share Pharmaceuticals & Biotechnology , FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 100 , FTSEurofirst 300 , FTSEurofirst 300 Ex Eurozone, FTSE 350 Higher Yield , FTSE 350 , FTSE Global 100, FTSE 350 Pharmaceuticals & Biotechnology , FTSE 100 , FTSE Techmark All Share , , , |
| Exchange | London Stock Exchange (Full) |
| Shares in Issue | 4,988,549,763 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | G S K House 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom |
| Web | https://www.gsk.com/ |
| Phone | +44 20 80475000 |
| Contact | () |
| Auditors | PricewaterhouseCoopers LLP |
